Neuren Pharmaceuticals Says US Partner Reports Higher Q4 2025 Daybue Sales; Shares Up 6%

MT Newswires Live

02/26

Neuren Pharmaceuticals (ASX:NEU) said its US partner Acadia Pharmaceuticals reported fourth-quarter 2025 Daybue net sales of $110 million, up 13% from a year earlier, according to a Thursday Australian bourse filing.

Daybue, or trofinetide, is the company's oral Rett syndrome drug approved by the US Food and Drug Administration, Health Canada, and the Ministry of Health in Israel. The company granted Acadia an exclusive worldwide license to develop and commercialize trofinetide.

Acadia expects 2026 Daybue net sales of $460 million to $490 million, implying royalty income to Neuren of AU$70 million to AU$77 million, per the filing.

Neuren Pharmaceuticals' shares rose past 6% in recent Thursday trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2614060270"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614060270\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614060270?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 12:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614060270","market":"fut","top_or_hot":-1,"title":"Neuren Pharmaceuticals Says US Partner Reports Higher Q4 2025 Daybue Sales; Shares Up 6%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> (ASX:NEU) said its US partner Acadia Pharmaceuticals reported fourth-quarter 2025 Daybue net sales of $110 million, up 13% from a year earlier, according to a Thursday Australian bourse filing.</p><p>Daybue, or trofinetide, is the company's oral Rett syndrome drug approved by the US Food and Drug Administration, Health Canada, and the Ministry of <a href=\"https://laohu8.com/S/HIT\">Health in</a> Israel. The company granted Acadia an exclusive worldwide license to develop and commercialize trofinetide.</p><p>Acadia expects 2026 Daybue net sales of $460 million to $490 million, implying royalty income to Neuren of AU$70 million to AU$77 million, per the filing.</p><p>Neuren Pharmaceuticals' shares rose past 6% in recent Thursday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuren Pharmaceuticals Says US Partner Reports Higher Q4 2025 Daybue Sales; Shares Up 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuren Pharmaceuticals Says US Partner Reports Higher Q4 2025 Daybue Sales; Shares Up 6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-26 12:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> (ASX:NEU) said its US partner Acadia Pharmaceuticals reported fourth-quarter 2025 Daybue net sales of $110 million, up 13% from a year earlier, according to a Thursday Australian bourse filing.</p><p>Daybue, or trofinetide, is the company's oral Rett syndrome drug approved by the US Food and Drug Administration, Health Canada, and the Ministry of <a href=\"https://laohu8.com/S/HIT\">Health in</a> Israel. The company granted Acadia an exclusive worldwide license to develop and commercialize trofinetide.</p><p>Acadia expects 2026 Daybue net sales of $460 million to $490 million, implying royalty income to Neuren of AU$70 million to AU$77 million, per the filing.</p><p>Neuren Pharmaceuticals' shares rose past 6% in recent Thursday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEU.AU","symbol_name":"NEUREN PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2614060270","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614060270","pubTimestamp":1772078605,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neuren Pharmaceuticals  said its US partner Acadia Pharmaceuticals reported fourth-quarter 2025 Daybue net sales of $110 million, up 13% from a year earlier, according to a Thursday Australian bourse filing.Daybue, or trofinetide, is the company's oral Rett syndrome drug approved by the US Food and Drug Administration, Health Canada, and the Ministry of Health in Israel. The company granted Acadia an exclusive worldwide license to develop and commercialize trofinetide.Acadia expects 2026 Daybue net sales of $460 million to $490 million, implying royalty income to Neuren of AU$70 million to AU$77 million, per the filing.Neuren Pharmaceuticals' shares rose past 6% in recent Thursday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NEU.AU":"NEUREN PHARMACEUTICALS LTD","BK7508":"医药生物股","BK7096":"制药"},"translate_title":"Neuren Pharmaceuticals表示，美国合作伙伴报告2025年第四季度Daybue销售额较高；股价上涨6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":1},"content_text":"Neuren Pharmaceuticals (ASX:NEU) said its US partner Acadia Pharmaceuticals reported fourth-quarter 2025 Daybue net sales of $110 million, up 13% from a year earlier, according to a Thursday Australian bourse filing.Daybue, or trofinetide, is the company's oral Rett syndrome drug approved by the US Food and Drug Administration, Health Canada, and the Ministry of Health in Israel. The company granted Acadia an exclusive worldwide license to develop and commercialize trofinetide.Acadia expects 2026 Daybue net sales of $460 million to $490 million, implying royalty income to Neuren of AU$70 million to AU$77 million, per the filing.Neuren Pharmaceuticals' shares rose past 6% in recent Thursday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}